ERS Clinical Practice Guidelines: high-flow nasal cannula in acute respiratory failure.

Oczkowski, Simon; Ergan, Begüm; Bos, Lieuwe; Chatwin, Michelle; Ferrer, Miguel; Gregoretti, Cesare; Heunks, Leo; Frat, Jean-Pierre; Longhini, Federico; Nava, Stefano; Navalesi, Paolo; Uğurlu, Aylin Ozsancak; Pisani, Lara; Renda, Teresa; Thille, Arnaud W; Winck, João Carlos; Windisch, Wolfram; Tonia, Thomy; Boyd, Jeanette; Sotgiu, Giovanni; ... (2022). ERS Clinical Practice Guidelines: high-flow nasal cannula in acute respiratory failure. European respiratory journal, 59(4), p. 2101574. European Respiratory Society 10.1183/13993003.01574-2021

Preview	Text Oczkowski_EurRespirJ_2021_AAM.pdf - Accepted Version Available under License Publisher holds Copyright. Download (7MB) | Preview
	Text Oczkowski_EurRespirJ_2022.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (688kB) | Request a copy

BACKGROUND

High-flow nasal cannula (HFNC) has become a frequently used non-invasive form of respiratory support in acute settings, however evidence supporting its use has only recently emerged. These guidelines provide evidence-based recommendations for the use of HFNC alongside other noninvasive forms of respiratory support in adults with acute respiratory failure (ARF).

MATERIALS AND METHODOLOGY

The European Respiratory Society Task Force panel included expert clinicians and methodologists in pulmonology and intensive care medicine. The Task Force used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) methods to summarise evidence and develop clinical recommendations for the use of HFNC alongside conventional oxygen therapy (COT) and non-invasive ventilation (NIV) for the management of adults in acute settings with ARF.

RESULTS

The Task Force developed 8 conditional recommendations, suggesting using: 1) HFNC over COT in hypoxemic ARF, 2) HFNC over NIV in hypoxemic ARF, 3)HFNC over COT during breaks from NIV, 4) either HFNC or COT in post-operative patients at low risk of pulmonary complications, 5) either HFNC or NIV in post-operative patients at high risk of pulmonary complications, 6) HFNC over COT in non-surgical patients at low risk of extubation failure, 7) NIV over HFNC for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV, 8) trialling NIV prior to use of HFNC in patients with chronic obstructive pulmonary disease (COPD) and hypercapnic ARF.

CONCLUSIONS

HFNC is a valuable intervention in adults with ARF. These conditional recommendations can assist clinicians in choosing the most appropriate form of non-invasive respiratory support to provide to patients in different acute settings.

Interest & Impact

Downloads

3 since deposited on 22 Oct 2021
3 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item